Napigen, Inc.
Napigen aims to harness the potentials of mitochondria and chloroplasts through proprietary organelle genome editing tools. Their technology offers opportunities in agriculture, human healthcare, and industrial biotechnology, with initial products focused on increasing crop yields and mitigating greenhouse gases to address global food security and environmental challenges.
Industries
Nr. of Employees
small (1-50)
Napigen, Inc.
200 Powder Mill Rd. | DIS-E500 | Wilmington, DE 19803
Patents
Products
Organelle genome editing technology platform
A technology platform enabling targeted modification of mitochondrial and chloroplast genomes for applications in agriculture, human healthcare, and industrial biotechnology.
Gene-edited cytoplasmic male sterility (CMS) crop lines (research-stage)
Research-stage gene-edited crop lines with mitochondrial edits conferring cytoplasmic male sterility intended to enable hybrid seed production; one example (rice) has received a regulatory determination referenced on the site.
Organelle genome editing technology platform
A technology platform enabling targeted modification of mitochondrial and chloroplast genomes for applications in agriculture, human healthcare, and industrial biotechnology.
Gene-edited cytoplasmic male sterility (CMS) crop lines (research-stage)
Research-stage gene-edited crop lines with mitochondrial edits conferring cytoplasmic male sterility intended to enable hybrid seed production; one example (rice) has received a regulatory determination referenced on the site.
Expertise Areas
- Organelle genome editing
- Plant trait engineering and hybrid seed systems
- Preclinical mitochondrial gene therapy research
- Metabolic engineering for industrial biosynthesis
Key Technologies
- Polynucleotide-guided endonucleases for organelle editing
- Mitochondrial transformation
- Chloroplast transformation
- Model organism genetics (yeast, Chlamydomonas)
News & Updates
The USDA’s Biotechnology Regulatory Services notified Napigen that its gene-edited mitochondrial rice plants are not subject to USDA regulation, marking a regulatory milestone for gene-edited mitochondrial DNA plants.
The U.S. Patent and Trademark Office issued a patent to Napigen for the use of CRISPR technologies to edit organellar genomes.
The Australian Patent Office granted a patent to Napigen for the use of CRISPR technologies to edit organellar genomes.
The U.S. Patent and Trademark Office issued a patent to Napigen for the use of CRISPR technologies to edit organellar genomes.
Napigen was awarded a USDA NIFA SBIR Phase I grant to develop a herbicide resistance trait that cannot transmit pollen to weeds, aiming to improve crop yields.
Napigen received the accelerators prize from the United Mitochondrial Disease Foundation, supporting mitochondrial disease research.
The USDA’s Biotechnology Regulatory Services notified Napigen that its gene-edited mitochondrial rice plants are not subject to USDA regulation, marking a regulatory milestone for gene-edited mitochondrial DNA plants.
The U.S. Patent and Trademark Office issued a patent to Napigen for the use of CRISPR technologies to edit organellar genomes.
The Australian Patent Office granted a patent to Napigen for the use of CRISPR technologies to edit organellar genomes.
The U.S. Patent and Trademark Office issued a patent to Napigen for the use of CRISPR technologies to edit organellar genomes.
Napigen was awarded a USDA NIFA SBIR Phase I grant to develop a herbicide resistance trait that cannot transmit pollen to weeds, aiming to improve crop yields.
Napigen received the accelerators prize from the United Mitochondrial Disease Foundation, supporting mitochondrial disease research.